NICE
Low dose Victoza on track for NICE approval
September 10, 2010Sales and Marketing NICE, Novo Nordisk, Victoza
Novo Nordisk is on track to receive NICE approval for its type II diabetes drug Victoza, but will still have …
Janssen to appeal against Velcade decision
August 26, 2010Medical Communications, Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma
Celgene’s Thalidomide has been recommended by NICE for multiple myeloma ahead of Janssen-Cilag’s Velcade. A final appraisal determination says that …
NICE updates guidance for arthritis treatments
August 26, 2010Sales and Marketing NICE, Roche, rheumatoid arthritis
Five new drugs for rheumatoid arthritis have been given the thumbs up by NICE as second line treatment. Roche’s MabThera, …
Multaq given limited approval from NICE
August 25, 2010Medical Communications, Sales and Marketing Multaq, NICE, Sanofi-Aventis, atrial, dronedarone
NICE has given a restricted approval to Sanofi-Aventis’s Multaq as a second line treatment for atrial fibrillation patients. The guidance …
Avastin patient access scheme too complicated, says NICE
August 25, 2010Sales and Marketing NICE, avastin, patient access
NICE is set to say no again to Avastin for use in patients with colorectal cancer. Avastin was first launched …
Pharma sector a ‘market for lemons’
August 20, 2010Sales and Marketing NICE, health economics
American sociologist Donald Light has made a provocative assessment of the pharma industry, saying the industry is able to exaggerate …
NICE decides Xolair is not value for money
August 12, 2010Sales and Marketing NICE, Novartis, Xolair
NICE has refused to back the use of Novartis’ Xolair for young children, saying the asthma drug’s cost brings little …
NICE: the end of an era
August 9, 2010Sales and Marketing Andrew Lansley, NICE, VBP, government
NICE is undergoing a momentus shift in its role which will see it leave behind the frequent clashes and controversy …
GPs urged to curb spending on prescriptions
August 6, 2010GPs, NHS, NICE, NPC, prescriptions
GPs are being encouraged to reduce spending on prescriptions by following NICE’s cost-effectiveness guidelines. A new National Prescribing Centre (NPC) …
Generic clopidogrel helps NICE recommend blood clot prevention
August 5, 2010Sales and Marketing NICE, Plavix
NICE has given preliminary approval for wider use of Sanofi-Aventis’s Plavix and Boehringer Ingelheim’s Persantine to prevent blood clots. It …
NICE set to recommend chronic constipation treatment
August 4, 2010Sales and Marketing Movetis, NICE, Resolor
NICE has provisionally recommended Belgium-based Movetis’s Resolor as an option for the treatment of chronic constipation in women where laxatives …
NICE halts Prolia appraisal
August 2, 2010Sales and Marketing Amgen, NICE, Prolia
NICE says it has been forced to terminate a review of Amgen’s bone density drug Prolia after the US biotech …
NICE approves trio of cancer drugs
July 28, 2010Sales and Marketing Iressa, MabThera, NICE, Xeloda
NICE has given its final recommendation to a trio of drugs for the treatment of various cancers, which means the …
NICE gets expanded role in quango cull
July 27, 2010MHRA, NHS, NICE, government
The bonfire of the quangos has begun in earnest in the health sector, with 18 so-called “arm’s length bodies” cut …
New measures to help patients with mystery cancers
July 27, 2010CUP, Cancer, NHS, NICE
Patients whose cancer has spread to other parts of the body from an unknown primary location are to be given …
